Phase III KEYNOTE-204: Pembrolizumab vs Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin Lymphoma

A focused text activity providing an expert review of the evolution in CLL treatment during the past several years, from Clinical Care Options (CCO)

Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 6, 2022 Expired: October 5, 2023

Downloadable slideset on current best practices and standard treatments for the management of CLL/SLL in the first-line and relapsed settings, from Clinical Care Options (CCO).

Farrukh T. Awan, MD Nicole Lamanna, MD Released: October 5, 2022

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Download these expert-selected slides on anti-BCMA CAR T-cell and bispecific agents for relapsed/refractory myeloma, from Clinical Care Options (CCO).

Noopur Raje, MD Released: September 22, 2022